Medical researcher explores economic impact of psychedelic therapy implementation

Emory University Fayzan Rab discusses groundbreaking research in exclusive Genomic Press Interview

2024-12-31

(Press-News.org) ATLANTA, Georgia, USA, 31 December 2024 - In a comprehensive Genomic Press Interview, Emory University MD candidate Fayzan Rab shares insights into his pioneering research on the economic and public health implications of psychedelic therapy implementation. Rab's work at the Emory Center for Psychedelics and Spirituality bridges the gap between clinical research and real-world healthcare delivery systems.

"It would be a fool's errand to say that psychedelic therapies alone would change that," says Rab, discussing mental healthcare challenges. "Treating mental illness will require changes within clinical practice but also investments into social safety nets, re-employment opportunities, and affordable housing."

Rab brings a unique perspective to psychedelic research, having previously led product development at Google and Mindstrong Health before pursuing medicine. His recent publication in Psychedelics, co-authored with Raison and Marseille, provides the first comprehensive estimate of potential patient demand for psilocybin therapy in depression treatment.

The research tackles critical implementation questions often overlooked in psychedelic science. While many studies focus on clinical trials, Rab investigates broader systemic challenges: healthcare accessibility, cultural inclusion, and economic viability. His work particularly emphasizes the importance of making these innovative treatments accessible to traditionally underserved communities.

"My hope in psychedelic science is that we get to integrate those questions early on while psychedelic therapies are in their infancy," Rab explains. "By addressing and planning for them now, I believe these therapies could reach and become more accessible to those generally excluded from treatment innovations."

Beyond traditional mental health applications, Rab has an interest in expanding the scope of psychedelic research to new populations including healthcare workers, cancer patients, and post-partum mothers and those with chronic pain. His work emphasizes the importance of community partnerships in developing research questions, particularly in his studies of Muslim communities' perspectives on psychedelic therapies.

The Genomic Press Interview offers unique insights into Rab's methodology and vision. His research group operates on two fundamental principles: maintaining narrow focus while seeking broader applications, and valuing progress over perfection. This approach has enabled meaningful contributions to the field while maintaining scientific rigor.

Dr. Charles Raison, Director of Research at the Emory Center for Psychedelics and Spirituality, notes: "Rab's research addresses crucial questions about implementation and accessibility that will shape the future of psychedelic medicine."

Fayzan Rab’s Genomic Press interview is part of a larger series that highlights the people behind today’s most influential scientific ideas. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that delve into the scientist’s impact on the field, while also touching on broader human themes. More information on the research leaders and research rising stars featured by Genomic Press can be found in our publication website: https://genomicpress.kglmeridian.com/.

The full Genomic Press Interview, titled “Fayzan Rab: What are the economic and public health implications of psychedelic therapies?,” is available on 24 December 2024 in Psychedelics, offering readers an unparalleled opportunity to explore the thoughts and experiences of one of the most influential minds in neuroscience and neurobiology of brain disorders. The article is freely available online at https://doi.org/10.61373/pp024k.0046.

About Psychedelics – Psychedelics: The Journal of Psychedelic Pharmacology (ISSN: 2997-2671) is a peer-reviewed medical research journal published by Genomic Press, New York. Psychedelics is exclusively dedicated to the latest advancements in the realm of psychedelic substances and their potential therapeutic uses. We embrace the full spectrum of research, from fundamental investigations to cutting-edge clinical studies. Psychedelics welcomes diverse perspectives and contributions, advancing the understanding of psychedelic compounds.

END

[Attachments] See images for this press release:

Medical researcher explores economic impact of psychedelic therapy implementation 2

ELSE PRESS RELEASES FROM THIS DATE:

Improving immunotherapies for kidney cancer

2024-12-30

A Medical University of South Carolina Hollings Cancer Center researcher is exploring new ways to improve treatment options for kidney cancer patients. With funding from a Department of Defense (DOD) Academy of Kidney Cancer Investigators Early Career Scholar Award, Aguirre de Cubas, Ph.D., will investigate how the immune system can be boosted to detect and kill kidney tumors. Congress established the award in 2017 to support research with high potential impact and exceptional scientific merit. De Cubas’ approach focuses on reactivating the immune system to recognize and target cancer cells better, offering new possibilities for improving existing ...

Billing patients for portal messages could decrease message volume and ease physician workload

2024-12-30

Embargoed for release until 5:00 p.m. ET on Monday 30 December 2024     @Annalsofim          Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, ...

Study of Sherpas highlights key role of kidneys in acclimatization to high altitudes

2024-12-30

(Calgary) — A study from a Mount Royal University physiologist and his team demonstrates the key role of the kidneys in acclimatization to high altitude, and illustrates another way that Sherpas are better adapted to high altitude ascent. Results from the study were recently published in in the prestigious international science journal Proceedings of the National Academy of Sciences. The paper, “Comparing integrative ventilatory and renal acid-base acclimatization in lowlanders and Tibetan highlanders during ascent to 4,300 m”, describes findings ...

Smartphone app can help reduce opioid use and keep patients in treatment, UT Health San Antonio study shows

2024-12-30

SAN ANTONIO, Dec. 30, 2024 – Patients with opioid use disorder can reduce their days of opioid use and stay in treatment longer when using a smartphone app as supportive therapy in combination with medication, a new study by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) shows. The cohort study of 600 underserved patients found that those who chose to use the app – which combines contingency management behavioral therapy and recovery support from peers – and alongside medication, reduced their days of opioid use by 35% compared with ...

Improved health care value cannot be achieved by hospital mergers and acquisitions alone

2024-12-30

Key Takeaways A new study finds little evidence that hospital mergers and acquisitions reduce costs or improve quality of care. More strategic quality improvement efforts are needed for patients to benefit from health care integration. CHICAGO (December 30, 2024) — Mergers and acquisitions of U.S. hospitals and health systems rarely improve the quality of care delivered or result in lower health care costs and prices, according to a study published in the Journal of the American College of Surgeons (JACS). The study, a systematic review of hundreds of published ...

People who are immunocompromised may not produce enough protective antibodies against RSV after vaccination

2024-12-30

FOR IMMEDIATE RELEASE Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity — primarily organ transplant recipients who take immunosuppressive medications to reduce the risk of rejection and others with immune system disorders — do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same age group with normal immune function. The study, conducted by a research team at the Johns Hopkins Transplant Research Center, was published today in the Journal of the American ...

Does coffee prevent head and neck cancer?

2024-12-30

In a new analysis of data from more than a dozen studies, coffee and tea consumption was linked with lower risks of developing head and neck cancers, including cancers of the mouth and throat. Cancers of the head and neck are the seventh most common forms of cancer worldwide, and rates are rising in low- and middle-income countries. Many studies have assessed whether drinking coffee or tea is associated with head and neck cancer, with inconsistent results. To provide additional insight, investigators led by the University of Utah’s Huntsman Cancer Institute examined data from ...

AI replaces humans in identifying causes of fuel cell malfunctions

2024-12-30

Dr. Chi-Young Jung's research team from the Hydrogen Research & Demonstration Center at the Korea Institute of Energy Research (KIER) has successfully developed a method to analyze the microstructure of carbon fiber paper, a key material in hydrogen fuel cells, at a speed 100 times faster than existing methods. This was achieved by utilizing digital twin technology and artificial intelligence (AI) learning. Carbon fiber paper is a key material in hydrogen fuel cell stacks, playing a crucial role in facilitating water discharge ...

Pitfalls of FDA-approved germline cancer predisposition tests

2024-12-30

“The FDA approval on September 29, 2023, for ‘class III de novo’ blood tests to assess hereditary cancer risk make widely available tests that may be obtained through a Direct to Consumer (DTC) path.” BUFFALO, NY – December 30, 2024 – A new editorial was published in Oncotarget’s Volume 15 on December 24, 2024, titled “Pitfalls and perils from FDA-approved germ-line cancer predisposition tests.“ Authored by Dr. Wafik S. El-Deiry, Editor-in-Chief of Oncotarget, and Dr. Eli Y. Adashi from Brown University, the article highlights concerns about the risks ...

A rising trend of 'murderous verbs' in movies over 50 years

2024-12-30

The amount of murdering and killing in movies has increased overall over the past 50 years, according to a new study that analyzed a massive database of film dialogue. Researchers used machine learning to search a database of subtitles from more than 160,000 English-language movies produced from 1970 to 2000. They calculated the amount of dialogue from characters using variations of the words “murder” or “kill” in each of the films. While the total use of these “murderous verbs” varied widely from year to year, there was a clear increasing trend over the five-decade ...